|Commissioned research: Q2 a non-event – pipeline on track|
|Saniona’s Q2 report was largely uneventful, with no change in the underlying revenue and cost trends. As the stock is trading on pipeline news rather than quarterly numbers, we consider it important that management said it believes pipeline progression is on track for readouts soon, with Tesomet ph IIa data in Prader-Willi syndrome and Tesofensine ph III top-line data in obesity both expected around Q1 2019.
Marketing material commissioned by Saniona.
To learn more on Commissioned Research, please click here
The information provided within this website is intended for background information only. The views and other information provided herein are the current views of Nordea Markets as of the date of publication and are subject to change without notice. The information provided within this website is not an exhaustive description of the described product or the risks related to it, and it should not be relied on as such, nor is it a substitute for the judgement of the recipient.
The information provided within this website is not intended to constitute and does not constitute investment advice nor is the information intended as an offer or solicitation for the purchase or sale of any financial instrument. The information provided within this website has no regard to the specific investment objectives, the financial situation or particular needs of any particular recipient. Relevant and specific professional advice should always be obtained before making any investment or credit decision. It is important to note that past performance is not indicative of future results.
Nordea Markets is not and does not purport to be an adviser as to legal, taxation, accounting or regulatory matters in any jurisdiction.
The information provided within this website may not be reproduced, distributed or published for any purpose without the prior written consent from Nordea Markets.